{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:39:45Z","timestamp":1773869985505,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine associations of systemic medications with the incidence and growth of geographic atrophy (GA) in participants of the comparison of age-related macular degeneration treatments trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Participants of comparison of age-related macular degeneration treatments trials with new untreated choroidal neovascularization in the study eye (one study eye per participant) were randomized to receive treatment with bevacizumab or ranibizumab. Participants were released from clinical trial treatment at 2 years and examined at approximately 5 years. Color fundus photographs and fluorescein angiograms taken at baseline, Years 1, 2, and 5 were assessed for the presence and size of GA by two masked graders. Participants were interviewed about systemic medication use at baseline. Systemic medications previously reported to be associated with age-related macular degeneration were evaluated for associations with GA incidence in study eye using univariable and multivariable Cox models and for association with the GA growth using linear mixed effects models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In multivariable analysis of 1,011 study eyes without baseline GA, systemic medications, including cholinesterase inhibitors, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein-coupled receptors, were not associated with GA incidence in the study eye (all adjusted hazard ratios \u22641.86, <jats:italic toggle=\"yes\">P<\/jats:italic> \u2265 0.18). In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with a higher GA growth rate (0.40 vs. 0.30 mm\/year, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>None of the systemic medications analyzed were associated with GA incidence. However, calcium channel blockers were associated with a higher growth rate of GA in the study eye.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003075","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T19:00:15Z","timestamp":1608058815000},"page":"1455-1462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS"],"prefix":"10.1097","volume":"41","author":[{"given":"Delu","family":"Song","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiying","family":"Hua","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"VanderBeek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua L.","family":"Dunaief","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan E.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebenezer","family":"Daniel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Martin","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Shuang","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the CATT Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250607","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCRESAHA.110.223875","article-title":"Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity","volume":"108","author":"Miller","year":"2011","journal-title":"Circ Res"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.2260","article-title":"Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyes","volume":"16","author":"Palczewska","year":"2010","journal-title":"Nat Med"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1167\/iovs.12-11481","article-title":"Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma","volume":"54","author":"Almasieh","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/157488608783333952","article-title":"Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study","volume":"3","author":"Etminan","year":"2008","journal-title":"Curr Drug Saf"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ajo.2006.11.058","article-title":"Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam Ancillary Study","volume":"143","author":"Klein","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ophtha.2016.10.023","article-title":"\u03b2-Blockers and neovascular age-related macular degeneration","volume":"124","author":"Yeung","year":"2017","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/IAE.0000000000002059","article-title":"Systemic beta-blockers and risk of progression to neovascular age-related macular degeneration","volume":"39","author":"Kolomeyer","year":"2019","journal-title":"Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archopht.118.3.351","article-title":"Hypertension, cardiovascular disease, and age-related macular degeneration. Age-related macular degeneration risk factors study group","volume":"118","author":"Hyman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.2014.889680","article-title":"Does long-term aspirin use increase the risk of neovascular age-related macular degeneration?","volume":"13","author":"Christen","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.ophtha.2019.06.023","article-title":"The association of aspirin use with age-related macular degeneration progression in the age-related eye disease studies: age-related eye disease study 2 report no. 20","volume":"126","author":"Keenan","year":"2019","journal-title":"Ophthalmology"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/OPX.0b013e31818883e0","article-title":"Anti-inflammatory drug use and age-related macular degeneration","volume":"85","author":"Swanson","year":"2008","journal-title":"Optom Vis Sci Off Publ Am Acad Optom"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/IAE.0b013e318276e0cf","article-title":"Role of statins in the development and progression of age-related macular degeneration","volume":"33","author":"VanderBeek","year":"2013","journal-title":"Retina"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archopht.121.8.1099","article-title":"Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane","volume":"121","author":"Hahn","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1167\/iovs.09-4000","article-title":"Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms","volume":"51","author":"Edwards","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/bjophthalmol-2012-302461","article-title":"Lactation, female hormones and age-related macular degeneration: the Troms\u00f8 Study","volume":"97","author":"Erke","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R19-20250607","first-page":"2224","article-title":"Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3","volume":"107","year":"2000","journal-title":"Ophthalmology"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-010715-103033","article-title":"Systems pharmacology links GPCRs with retinal degenerative disorders","volume":"56","author":"Chen","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.oret.2020.07.006","article-title":"Quantification of geographic atrophy using spectral domain optical coherence tomography in age-related macular degeneration","volume":"5","author":"Cleland","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40266-013-0061-4","article-title":"Do statins have a role in the prevention of age-related macular degeneration?","volume":"30","author":"Tsao","year":"2013","journal-title":"Drugs Aging"},{"key":"R26-20250607","article-title":"Screening medications for association with progression to wet age-related macular degeneration (AMD)","author":"Wang","year":"2020","journal-title":"Ophthalmology"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/IAE.0000000000002295","article-title":"Association between oral iron supplementation and retinal or subretinal hemorrhage IN the comparison OF age-related macular degeneration treatment trials","volume":"39","author":"Song","year":"2019","journal-title":"Retina"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bjophthalmol-2018-312305","article-title":"Paramacular temporal atrophy in sickle cell disease occurs early in childhood","volume":"103","author":"Martin","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2014.03.005","article-title":"Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study","volume":"121","author":"Klein","year":"2014","journal-title":"Ophthalmology"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.ophtha.2015.08.028","article-title":"The association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9","volume":"122","author":"Al-Holou","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:07:06Z","timestamp":1749319626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003075","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}